Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2026-05-19 18:04:44 ET · period of report 2026-05-15 · accession 0000897069-26-001184 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 18:04 | 2026-05-15 | PCSA | Young David | Pres. Research, Development, Dir | P - Purchase | $2.97 | +1,545 | 15.3K | +11% | +$4,589 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-15 | P | A | 1,545 | $2.97 | 15,345 | D | — | — | (F1) Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares. |